Bavarian Nordic A/S
Records under this name other than the patents Bavarian Nordic A/S holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 60 patents it holds.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,561,722 | Methods and Compositions for Enhancing Immune Responses Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 8,808,709 | Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents Term ended Term ended Nov 9, 2026 · USPTO record | Term ended | Term ended Nov 9, 2026 | USPTO record |
| US 8,859,257 | Vaccinia Virus Mutants Containing the Major Genomic Deletions of Mva No holder on record Lapsed on the fee record Ended Oct 14, 2026 · High confidence | Lapsed on the fee record | Ended Oct 14, 2026 | High confidence |
| US 9,265,823 | Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents Term ended Ended no later than Feb 17, 2026 · USPTO record | Term ended | Ended no later than Feb 17, 2026 | USPTO record |
| US 11,173,204 | MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen Lapsed on the fee record Ended Nov 16, 2025 · USPTO record | Lapsed on the fee record | Ended Nov 16, 2025 | USPTO record |
| US 7,695,939 | Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions Term ended Term ended Aug 23, 2025 · USPTO record | Term ended | Term ended Aug 23, 2025 | USPTO record |
| US 9,717,787 | Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine Lapsed on the fee record Ended Aug 1, 2025 · USPTO record | Lapsed on the fee record | Ended Aug 1, 2025 | USPTO record |
| US 11,020,476 | Methods and Compositions for Inducing an Immune Response Against Hepatitis B Virus (HBV) Formerly held Lapsed on the fee record Ended Jun 1, 2025 · High confidence | Lapsed on the fee record | Ended Jun 1, 2025 | High confidence |
| US 10,946,089 | Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine Lapsed on the fee record Ended Mar 16, 2025 · USPTO record | Lapsed on the fee record | Ended Mar 16, 2025 | USPTO record |
| US 10,925,956 | Methods and compositions for inducing protective immunity against a marburg virus infection Lapsed on the fee record Ended Feb 23, 2025 · USPTO record | Lapsed on the fee record | Ended Feb 23, 2025 | USPTO record |